Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Van Kerrebroeck

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
BJU International|November 26, 2002
Standardization of terminology in nocturia: commentary on the ICS reportP Van Kerrebroeck
BJU International|April 17, 2002
Denervation techniques have limited applicabilityP Van Kerrebroeck
BJU International|May 14, 2004
Duloxetine: an innovative approach for treating stress urinary incontinenceP Van Kerrebroeck
BJU International|February 16, 2000
Standardization and terminology of nocturiaP van Kerrebroeck, J Weiss
Paraplegia|November 1, 1995
The effects of 4 weeks treatment with cisapride on cystometric parameters in spinal cord injury patients. A double-blind, placebo controlled studyJ J Wyndaele, P Van Kerrebroeck
Acta Urologica Belgica|January 1, 1988
The hairless pediculate island flap in urethroplastyJ J Mattelaer, P Van Kerrebroeck
BJU International|July 31, 2003
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studiesC G Roehrborn, P Van Kerrebroeck, J Nordling
The Journal of Urology|June 21, 2011
Sacral neuromodulation as a treatment for chronic pelvic painT Marcelissen, R Jacobs, P van Kerrebroeck, et al.
European Urology|March 18, 2000
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study GroupP van Kerrebroeck, A Jardin, K U Laval, et al.
Acta Urologica Belgica|January 1, 1983
[Adenoma of the kidney and its relation to hypernephroma]P Van Kerrebroeck, P J Dhaenens, B Kaeckenbeeck, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
BJU International|November 26, 2002
Standardization of terminology in nocturia: commentary on the ICS reportP Van Kerrebroeck
BJU International|April 17, 2002
Denervation techniques have limited applicabilityP Van Kerrebroeck
BJU International|May 14, 2004
Duloxetine: an innovative approach for treating stress urinary incontinenceP Van Kerrebroeck
BJU International|February 16, 2000
Standardization and terminology of nocturiaP van Kerrebroeck, J Weiss
Paraplegia|November 1, 1995
The effects of 4 weeks treatment with cisapride on cystometric parameters in spinal cord injury patients. A double-blind, placebo controlled studyJ J Wyndaele, P Van Kerrebroeck
Acta Urologica Belgica|January 1, 1988
The hairless pediculate island flap in urethroplastyJ J Mattelaer, P Van Kerrebroeck
BJU International|July 31, 2003
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studiesC G Roehrborn, P Van Kerrebroeck, J Nordling
The Journal of Urology|June 21, 2011
Sacral neuromodulation as a treatment for chronic pelvic painT Marcelissen, R Jacobs, P van Kerrebroeck, et al.
European Urology|March 18, 2000
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study GroupP van Kerrebroeck, A Jardin, K U Laval, et al.
Acta Urologica Belgica|January 1, 1983
[Adenoma of the kidney and its relation to hypernephroma]P Van Kerrebroeck, P J Dhaenens, B Kaeckenbeeck, et al.
Pageof 3